glp-1 receptor agonist antipsychotic weight gain study Antipsychotic-Induced in Severe Mental Illness: Risk Factors and Special Considerations | Current Psychiatry Reports Antipsychotic-Induced Weight Gain: Are GLP-1

Long-term maintenance after completing dose escalation Once you reach your target maintenance dose and complete the initial adaptation period, the dose schedule enters its long-term phase

Label your vial Write the following on a small piece of tape and attach it to the vial: the reconstitution date, the amount of water added, and the resulting concentration

Differentiating IGH from Vitiligo Some of my patients worry that they may be developing Vitiligo, an autoimmune condition that typically presents with larger, stark white patches which can appear anywhere on the body, not only in sun-exposed areas

CagriSema submitted for FDA approval in December 2025 with expected approval in Q4 2026 or Q1 2027, meaning launch around mid-2027